PBAC's latest decision on Insulin degludec with insulin aspart: Recommended with restriction (2018). Considered for Treatment of adult patients with diabetes mellitus where insulin treatment is necessary. IDegAsp is indicated for improvement of glycaemic control in adult patients with diabetes mellitus requiring basal and prandial insulin.
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2017
Submissions
2
2017 → 2018
Eligible population
Adult patients with type 1 diabetes mellitus (T1DM), insulin-naïve type 2 diabetes mellitus (T2DM), and insulin-experienced type 2 diabetes mellitus (T2DM) requiring basal and prandial insulin treatment.
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes mellitus; biphasic insulin aspart 30 (BIAsp 30) in type 1 diabetes mellitus
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. The submission claimed IDegAsp is cost-neutral to BIAsp 30 in T2DM population.
Risk sharing
Risk-sharing arrangement in place — Special pricing arrangement (SPA) proposed with willingness to work with the Department to offer a condition to rebate the Government up-front (subject to appropriate reconciliation measures).
Submission history
Nov 2017: Recommended with restriction · Restricted
Mar 2018: Recommended with restriction · Unrestricted